Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022)

Aligos Therapeutics filings provide 3 years of Non-Current Deffered Revenue readings, the most recent being $1.6 million for Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue rose 13.49% to $1.6 million in Q3 2022 year-over-year; TTM through Sep 2022 was $1.6 million, a 13.49% increase, with the full-year FY2020 number at $4.1 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $1.6 million in Q3 2022 for Aligos Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $5.0 million in Q1 2022 to a low of $1.4 million in Q3 2021.
  • Median Non-Current Deffered Revenue over the past 3 years was $3.3 million (2022), compared with a mean of $3.1 million.
  • The widest YoY moves for Non-Current Deffered Revenue: up 42.83% in 2022, down 13.49% in 2022.
  • Aligos Therapeutics' Non-Current Deffered Revenue stood at $4.1 million in 2020, then plummeted by 66.63% to $1.4 million in 2021, then increased by 13.49% to $1.6 million in 2022.
  • The last three reported values for Non-Current Deffered Revenue were $1.6 million (Q3 2022), $3.3 million (Q2 2022), and $5.0 million (Q1 2022) per Business Quant data.